Call 1 (888) 460-6556 to speak with a counselor.

Assess the prevalence of non-opioid drug use among opioid-addicted, buprenorphine injecting individuals in Georgia, during and after a 12-week course of buprenorphine-naloxone (Suboxone®) or methadone. (Source: Journal of Substance Abuse Treatment)

MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space…

{ Comments on this entry are closed }

Call 1 (888) 460-6556 to speak with a counselor.

[Abstract unavailable]
Language: en… (Source: SafetyLit: All (Unduplicated))

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

{ Comments on this entry are closed }

Buprenorphine-Naloxone Therapy in Pain Management

October 1, 2014

No abstract available (Source: Survey of Anesthesiology) MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read the full article →

Table of Contents

September 26, 2014

Abstract SAMHSA Buprenorphine Meeting: Another Step Toward Lifting the Cap Fraud Probe of Sober Homes Highlights Drug‐Test Scams Bill Proposed to Provide Local Incentives to Treat Addiction N.J. Bill Would Allow Outpatient Commitment for Addiction California Certification: CAADAC + CAARR = CCAPP NASADAD Issues Public Policy Statement Endorsing Naloxone ASAM Revises Public Policy Statement on […]

Read the full article →

SUBOXONE (Buprenorphine Hydrochloride, Naloxone Hydrochloride) Film, Soluble [Lake Erie Medical DBA Quality Care Products LLC]

September 4, 2014

Updated Date: Sep 4, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read the full article →

A ‘Missing Not at Random’ (MNAR) and ‘Missing at Random’ (MAR) Growth Model Comparison with a Buprenorphine/Naloxone Clinical Trial

August 28, 2014

ConclusionsThis performance comparison of three missing data strategies (latent growth model, Diggle‐Kenward selection model, Wu‐Carrol selection model) on sample data indicates a need for increased use of sensitivity analyses in clinical trial research. Given the potential sensitivity of the trial arm effect to missing data assumptions, it is critical for researchers to consider whether the […]

Read the full article →

Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk? – Soyka M.

August 14, 2014

Opioid maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Risk of diversion and toxicity of opioid prescription drugs, including buprenorphine, causes significant concerns. This is particul… (Source: SafetyLit: All (Unduplicated)) MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read the full article →

BUNAVAIL (Buprenorphine And Naloxone) Film [BioDelivery Sciences International, Inc.]

August 6, 2014

Updated Date: Aug 6, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read the full article →

The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes

August 1, 2014

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of […]

Read the full article →

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users

July 23, 2014

Abstract In spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone. However, clinical research has not yet examined the utility of the combined formulation to deter […]

Read the full article →